# Study of Nab-Paclitaxel in High Risk Early Breast Cancer

> **NCT01690702** · PHASE3 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 2886 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** nab-Paclitaxel
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01690702
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2018-09-30
- **Final completion:** 2020-07-20
- **Target enrollment:** 2886 (ACTUAL)
- **Last updated:** 2021-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01690702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01690702, "Study of Nab-Paclitaxel in High Risk Early Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01690702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*